Latest news with #U.S.NationalInstitutesofHealth
Yahoo
28-05-2025
- Business
- Yahoo
Scientist.com Adds Trial Insights™ to Clinical Labs Navigator™ Solution, Giving Researchers Instant Access to Global Clinical-Trial Intelligence
SAN DIEGO, May 28, 2025--(BUSINESS WIRE)-- the leading R&D procurement platform for the life sciences, today integrated Trial Insights™—its real‑time clinical‑trial analytics tool—into Clinical Labs Navigator™. The move lets scientists source lab services and query more than 500,000 active and completed trials from a single dashboard, shortening study‑planning cycles from weeks to hours. "Trial Insights turns scattered public and proprietary trial records into a live, searchable map," said Ron Ronauro, Founder of Trial Insights and VP of Applications at "A team can pull up any study, filter by endpoints, inclusion/exclusion criteria, enrollment progress or regulatory status, and instantly spot trends—without wrestling with spreadsheets." What's New Inside Clinical Labs Navigator Global trial coverage – Search 17 primary registries by phase, indication and geography. Biomarker explorer – See which markers drive response and how they trend across studies. Investigator & site profiles – Rank investigators by experience, therapeutic focus and startup speed. Drug & sponsor analytics – Track pipelines, competitors and partnership history in one view. Smart alerts – Get email or in‑app notifications when a trial you follow changes status, geography or enrollment targets. Availability Trial Insights is now live for all Clinical Labs Navigator users. New users can start a free trial or book a demo at For a live demo of Trial Insights and/or Clinical Labs Navigator, visit booth #15157 at the upcoming ASCO Annual Meeting in Chicago, IL. About makes it easy for life‑science teams to find, vet and order the research services and products they need—often in days instead of weeks. Its online marketplace brings together 6,000+ pre‑qualified suppliers across 1,000‑plus research categories, all with built‑in regulatory and data‑privacy controls. The platform powers secure sourcing hubs for 20 of the world's top 30 pharmaceutical companies, 100+ biotech firms and the U.S. National Institutes of Health (NIH). Founded in 2007 and continually enhanced with AI tools, helps scientists spend less time on paperwork and more time on discovery. Learn more at Clinical Labs Navigator and Trial Insights are trademarks of View source version on Contacts Preci+1 877-644-3044marketing@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
Scientist.com Adds Trial Insights™ to Clinical Labs Navigator™ Solution, Giving Researchers Instant Access to Global Clinical-Trial Intelligence
SAN DIEGO--(BUSINESS WIRE)-- the leading R&D procurement platform for the life sciences, today integrated Trial Insights™—its real‑time clinical‑trial analytics tool—into Clinical Labs Navigator™. The move lets scientists source lab services and query more than 500,000 active and completed trials from a single dashboard, shortening study‑planning cycles from weeks to hours. enhances Clinical Labs Navigator solution with addition of Trial Insights, providing researchers in the life sciences with real-time insights into global clinical-trial data. 'Trial Insights turns scattered public and proprietary trial records into a live, searchable map,' said Ron Ronauro, Founder of Trial Insights and VP of Applications at 'A team can pull up any study, filter by endpoints, inclusion/exclusion criteria, enrollment progress or regulatory status, and instantly spot trends—without wrestling with spreadsheets.' What's New Inside Clinical Labs Navigator Global trial coverage – Search 17 primary registries by phase, indication and geography. Biomarker explorer – See which markers drive response and how they trend across studies. Investigator & site profiles – Rank investigators by experience, therapeutic focus and startup speed. Drug & sponsor analytics – Track pipelines, competitors and partnership history in one view. Smart alerts – Get email or in‑app notifications when a trial you follow changes status, geography or enrollment targets. Availability Trial Insights is now live for all Clinical Labs Navigator users. New users can start a free trial or book a demo at For a live demo of Trial Insights and/or Clinical Labs Navigator, visit booth #15157 at the upcoming ASCO Annual Meeting in Chicago, IL. About makes it easy for life‑science teams to find, vet and order the research services and products they need—often in days instead of weeks. Its online marketplace brings together 6,000+ pre‑qualified suppliers across 1,000‑plus research categories, all with built‑in regulatory and data‑privacy controls. The platform powers secure sourcing hubs for 20 of the world's top 30 pharmaceutical companies, 100+ biotech firms and the U.S. National Institutes of Health (NIH). Founded in 2007 and continually enhanced with AI tools, helps scientists spend less time on paperwork and more time on discovery. Learn more at Clinical Labs Navigator and Trial Insights are trademarks of
The Star
15-05-2025
- Health
- The Star
U.S. infant becomes first to receive personalized gene therapy for rare incurable disease
LOS ANGELES, May 15 (Xinhua) -- In a groundbreaking medical milestone, U.S. researchers have successfully developed and delivered a personalized gene-editing therapy to treat an infant suffering from a rare and life-threatening genetic disorder. The child, diagnosed shortly after birth with carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the first human to receive a customized CRISPR-based treatment targeting the root cause of the condition, according to a release of the U.S. National Institutes of Health (NIH) on Thursday. CPS1 deficiency is characterized by an inability to fully break down byproducts from protein metabolism in the liver, causing ammonia to build up to toxic levels in the body. It can cause severe damage to the brain and liver, according to NIH. A team of researchers at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed the customized therapy using the gene-editing platform CRISPR. They corrected a specific gene mutation in the baby's liver cells that led to the disorder. CRISPR is an advanced gene editing technology that enables precise changes to DNA inside living cells. This is the first known case of a personalized CRISPR-based medicine administered to a single patient and was carefully designed to target non-reproductive cells so changes would only affect the patient, according to NIH. The child initially received a very low dose of the therapy at six months of age, then a higher dose later. The research team saw signs that the therapy was effective almost from the start, according to NIH. Their findings were published Thursday in The New England Journal of Medicine. "As a platform, gene editing -- built on reusable components and rapid customization -- promises a new era of precision medicine for hundreds of rare diseases, bringing life-changing therapies to patients when timing matters most: Early, fast, and tailored to the individual," said Joni L. Rutter, director of NIH's National Center for Advancing Translational Sciences.
United News of India
15-05-2025
- Health
- United News of India
U.S. researchers identify tissue changes linked to aggressive breast cancer risk
Los Angeles, May 15 (UNI) Researchers at the U.S. National Institutes of Health (NIH) have identified structural changes in breast connective tissue that are linked to a higher risk of developing aggressive breast cancer, according to a new study published on Wednesday. The findings, published in the Journal of the National Cancer Institute, suggest that these changes, referred to as stromal disruption, could serve as a potential biomarker to identify women at greater risk, even before cancer develops. The research also found that stromal disruption is associated with poorer survival outcomes among women already diagnosed with invasive breast cancer. The team used machine learning to analyze over 9,000 breast tissue samples, including healthy breast tissues, benign breast disease biopsies, and cancerous tissues. They discovered that stromal disruption was more common in women with risk factors for aggressive breast cancer, such as obesity, Black race, early age, multiple childbirths, and a family history of the disease. In women with benign breast disease, substantial stromal disruption was linked to a significantly higher likelihood of developing breast cancer and a faster disease onset. Among breast cancer patients, those with greater stromal disruption were more likely to have aggressive cancer subtypes and lower survival rates, especially in estrogen receptor-positive cases. Such insights could help inform the development of cancer prevention and treatment strategies that target the stromal microenvironment. In addition, stromal disruption is inexpensive to assess and could be widely adopted, particularly in low-resource settings where molecular analysis is impractical or very expensive, according to the study. UNI XINHUA ARN
The Star
14-05-2025
- Health
- The Star
U.S. researchers identify tissue changes linked to aggressive breast cancer risk
LOS ANGELES, May 14 (Xinhua) -- Researchers at the U.S. National Institutes of Health (NIH) have identified structural changes in breast connective tissue that are linked to a higher risk of developing aggressive breast cancer, according to a new study published on Wednesday. The findings, published in the Journal of the National Cancer Institute, suggest that these changes, referred to as stromal disruption, could serve as a potential biomarker to identify women at greater risk, even before cancer develops. The research also found that stromal disruption is associated with poorer survival outcomes among women already diagnosed with invasive breast cancer. The team used machine learning to analyze over 9,000 breast tissue samples, including healthy breast tissues, benign breast disease biopsies, and cancerous tissues. They discovered that stromal disruption was more common in women with risk factors for aggressive breast cancer, such as obesity, Black race, early age, multiple childbirths, and a family history of the disease. In women with benign breast disease, substantial stromal disruption was linked to a significantly higher likelihood of developing breast cancer and a faster disease onset. Among breast cancer patients, those with greater stromal disruption were more likely to have aggressive cancer subtypes and lower survival rates, especially in estrogen receptor-positive cases. Such insights could help inform the development of cancer prevention and treatment strategies that target the stromal microenvironment. In addition, stromal disruption is inexpensive to assess and could be widely adopted, particularly in low-resource settings where molecular analysis is impractical or very expensive, according to the study.
